Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 6/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.47 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1756329 | 0.88 | MAOB (0.49) | RAB9ANPC1LMNAMRGPRX4MAOB | |
| SCHEMBL23978033 | 0.85 | MRGPRX4 (0.69) | RAB9ANPC1MRGPRX4MAOBMAOA | |
| SCHEMBL2009729 | 0.82 | MAOB (0.56) | MRGPRX4MAOBMAPTALDH1A1GAA | |
| SCHEMBL18216620 | 0.81 | CA12 (0.47) | LMNAMRGPRX4MAPTALDH1A1GAA | |
| SCHEMBL1756342 | 0.81 | GYS1 (0.53) | ALDH1A1GAA | |
| SCHEMBL10397860 | 0.80 | NR4A2 (0.72) | RAB9ANPC1LMNAMAOBMAOA | |
| SCHEMBL31371189 | 0.79 | CA12 (0.49) | NPC1LMNAMRGPRX4MAPTALDH1A1 | |
| SCHEMBL12808621 | 0.79 | CA12 (0.49) | NPC1LMNAMRGPRX4MAPTALDH1A1 | |
| SCHEMBL1444069 | 0.79 | MAOB (0.74) | RAB9ANPC1LMNAMAOBMAPT | |
| SCHEMBL11218725 | 0.79 | NPC1 (0.86) | RAB9ANPC1LMNAMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11622970-B2 | BCL-2 inhibitors and their use as pharmaceuticals | Prelude Therapeutics Incorporation (US) | 2023-04-11 | — | — | US | disclosed |
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-11-11 | — | — | US | disclosed |
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-11-11 | — | — | US | disclosed |
| WO-2021222174-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222174-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | BCL2, BCL2L2, BCL2L1 | RAB9A 2735/4885NPC1 2268/4885LMNA 1095/4885 |
| US-11622970-B2 | BCL-2 inhibitors and their use as pharmaceuticals | BCL2, BCL2L2, BCL2L1 | RAB9A 2735/4885NPC1 2268/4885LMNA 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.